Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

Independent Director at Matinas BioPharma Holdings, Inc. (starting in 2025), and Executive Advisor at Methuselah Capital Management LLC. Former jobs include Vice Chairman at Alliance for ...

Mr. Neugeboren is currently an Independent Director at Matinas BioPharma Holdings, Inc., starting in 2025. Mr. Neugeboren is currently the Chief Strategy Officer at Cronus Pharma LLC, starting in ...

plus a U.K. headquarters for the German biopharma in London, which will also house an artificial intelligence “hub” led by BioNTech’s AI subsidiary InstaDeep. As part of the commitment ...

Bristol Myers Squibb leapt into the drug industry’s most intense new rivalry on Monday, signing a deal to potentially spend ...

BNT327, a bispecific antibody candidate under development by BioNTech (NASDAQ:BNTX) that is seen as critical to the biotech's future success, will compete favorably against rival Summit ...

Moderna is suing Pfizer and BioNTech, accusing the companies of infringing on Moderna’s patents when they partnered to develop their own COVID-19 vaccine. Moderna is suing Pfizer and BioNTech ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on BioNTech BNTX in the last three months. The table below summarizes their recent ratings ...